| Title |
Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, January 2012
|
| DOI | 10.2147/ndt.s17923 |
| Pubmed ID | |
| Authors |
Carrie Robertson, Carrie Robertson, Ivan Garza |
| Abstract |
OnabotulinumtoxinA, a neurotoxin, has been studied in numerous trials as a novel preventive therapy for migraine headache. The data would support that it may be effective at reducing headache days in patients suffering from chronic migraine (≥15 headache days/month, with eight or more of those migraine headache days). The mechanism by which onabotulinumtoxinA exerts its effects on migraine is not yet understood. It is known to inhibit acetylcholine release at the neuromuscular junction, but this probably does not explain the observed antinociceptive properties noted in preclinical and clinical trials. This review will discuss the known mechanisms of action of botulinum toxin type A, and will review the available randomized, placebo-controlled trials that have looked at its efficacy as a migraine preventative. We also describe the onabotulinumtoxinA injection sites used at our institution. |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 1% |
| Netherlands | 1 | 1% |
| Unknown | 65 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 18% |
| Other | 7 | 10% |
| Student > Ph. D. Student | 7 | 10% |
| Student > Master | 6 | 9% |
| Student > Bachelor | 6 | 9% |
| Other | 19 | 28% |
| Unknown | 10 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 54% |
| Agricultural and Biological Sciences | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Neuroscience | 3 | 4% |
| Nursing and Health Professions | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 14 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 May 2012.
All research outputs
#22,758,309
of 25,373,627 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,584
of 3,132 outputs
Outputs of similar age
#228,487
of 250,101 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#8
of 8 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,101 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one.